Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Last updated date
Last updated date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (3)
Type
Type
Guidance (797)
Guidance programme
(
1 selected
)
Guidance programme
Antimicrobial prescribing guidelines (20)
Cancer service guidelines (8)
Clinical guidelines (225)
COVID-19 rapid guidelines (3)
Diagnostics guidance (50)
Health technology evaluations (18)
Highly specialised technologies guidance (28)
Interventional procedures guidance (603)
Medical technologies guidance (67)
Medicines practice guidelines (5)
NICE guidelines (341)
Public health guidelines (61)
Safe staffing guidelines (2)
Social care guidelines (71)
Technology appraisal guidance (797)
Apply filters
Showing 331 to 340 of 797
Sort by
Date
Title
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
TA694
28 April 2021
28 April 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
TA695
28 April 2021
28 April 2021
Avelumab for treating metastatic Merkel cell carcinoma
TA517
11 April 2018
21 April 2021
Acalabrutinib for treating chronic lymphocytic leukaemia
TA689
21 April 2021
21 April 2021
Avelumab for untreated metastatic Merkel cell carcinoma
TA691
21 April 2021
21 April 2021
Anakinra for treating Still's disease
TA685
31 March 2021
31 March 2021
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
TA686
31 March 2021
31 March 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
TA687
31 March 2021
31 March 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
TA684
17 March 2021
17 March 2021
Erenumab for preventing migraine
TA682
10 March 2021
10 March 2021
Previous page
1
…
32
33
Current page
34
35
36
…
80
Page
34
of
80
Next page
Results per page
10
25
50
All
Back to top